Dr. Jonathan Thompson, M.D.
Hematology & Oncology (Hematology & Oncology Physician)
9200 W Wisconsin Ave
Milwaukee, WI 53226
Who else practices at this address →
Milwaukee County includes primary care (32% of residents) and mental health (34% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Medical College of Wisconsin (2010)
- Years since graduation
- 16
- In the NPI registry since
- 2010
- Medicare patients seen, 2024
- 150
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2010Medical school: Medical College of Wisconsin
- 2010Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WI license 56964 -
Internal Medicine Physician
WI license 56964-20
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Froedtert Memorial Lutheran Hospital Milwaukee, WI
- Community Memorial Hospital Menomonee Falls, WI
- St Josephs Community Hospital West Bend West Bend, WI
Medical groups
- The Medical College of Wisconsin Inc (2,115 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 150
- Services billed
- 870
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 40-54 minutes | 415 | 116 |
| Established patient office or other outpatient visit, 30-39 minutes | 142 | 77 |
| Established patient office or other outpatient visit, 20-29 minutes | 58 | 41 |
| New patient office or other outpatient visit, 60-74 minutes | 39 | 39 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Dexamethasone Other prescribers in Milwaukee, WI | 83 |
| Ondansetron Hcl Other prescribers in Milwaukee, WI | 73 |
| Olanzapine Other prescribers in Milwaukee, WI | 52 |
| Tagrisso (osimertinib mesylate) | 26 |
| Erlotinib Hcl | 23 |
| Folic Acid Other prescribers in Milwaukee, WI | 20 |
| Gabapentin Other prescribers in Milwaukee, WI | 18 |
| Oxycodone Hcl Other prescribers in Milwaukee, WI | 16 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Milwaukee, WI | 13 |
| Prednisone Other prescribers in Milwaukee, WI | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 11 companies. The companies reported $408,288 in research payments for these studies, mostly to the institutions running them.
- A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Daiichi Sankyo Inc. · Recruiting · NCT06362252 - An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Phase 1 Study of INBRX 106 and INBRX-106 in Combination with Pembrolizumab in Subjects with Locally Advanced or Metastatic Solid Tumors
Merck Sharp & Dohme LLC - A randomized phase 3 openlabel study to evaluate SGNB6A compared with docetaxel in adult subjects with previously treated nonsmall cell lung cancer
Pfizer Inc. - A Phase 2, Multicenter, Randomized, Open-Label Trial of GEN1046 as Monotherapy and in Combination With Anti-cancer Therapy in Subjects With Relapsed/Refractory Metastatic Non-Small Cell Lung Cancer After Treatment Wit…
Genmab U.S., Inc. - NCT05361174
Iovance Biotherapeutics, Inc. - Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations
Daiichi Sankyo Inc. · Active, not recruiting · NCT05215340 - Phase 1 First-In-Human Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 794 in Participants With Claudin 6-positive Advanced/Metastatic Non-small Cell Lung Cancer, Epithelial Ovarian Cancer, and …
Amgen Inc. - A Phase III, double-blind, placebo-controlled, Randomized, Multicenter, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced Stage III, Unresectable Non-sm…
AstraZeneca Pharmaceuticals LP - Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
Beone Medicines USA, Inc. · Completed · NCT04047862 - Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
Mirati Therapeutics, Inc. · Terminated · NCT03906071
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.